Bio-Rad falls after Q1 net loss, cuts 2026 revenue outlook

Sartorius AG

01/05/2026 17:52

** Shares of life sciences firm Bio-Rad Laboratories BIO.N fall 9.5% to $253.48

** Co now expects 2026 revenue to range from a decline of nearly 3% to growth of 0.5%, compared with its prior forecast of 0.5% to 1.5% growth

** Posts a Q1 net loss of $527.1 million, compared with net income of $64 million a year earlier, mainly due to a fair-value change in its Sartorius AG investment

** On an adjusted basis, co posts Q1 EPS of $1.89 per share, vs analysts' estimate of $1.98 per share - LSEG-compiled data

** Including session's moves, BIO down 16.7% YTD

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))